Prevalence of type 2 diabetes mellitus and chronic liver disease: A retrospective study of the association of two increasingly common diseases in Mexico

Annals of Hepatology

Volumn 9, Issue 3, 2010, Pages 282-288

  Kobashi Margain, Ramon Arturo ^a   Gutierrez Grobe, Ylse ^a   Ponciano Rodriguez, Guadalupe ^b   Uribe, Misael ^a   Mendez Sanchez, Nahum ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Chronic liver disease; Cirrhosis; Hepatocellular carcinoma; Insulin resistance; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY SIZE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SEX RATIO; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; AGED; CHRONIC DISEASE; FATTY LIVER; LIVER TUMOR; MIDDLE AGED;

ADULT; AGE DISTRIBUTION; AGED; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MEXICO; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 79952053179     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31638-2     Document Type: Article

References (46)

1. Mendez-Sanchez N, Villa AR, Vazquez-Elizondo G, Poncia-no-Rodriguez G, Uribe M. Mortafity trends for liver cancer in Mexico from 2000 to 2050. Ann Hepatol 2005; 7(3): 226-9.
2. Data from the Direccion General de Epidemiologic, available at http://sinais.salud.gob.mx/mortalidad.
3. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8(1): S40-S43.
4. Aguilar-Salinas CA, Velasquez-Monroy O, Gomez-Perez FJ, et al. Characteristics of the patients with type 2 diabetes in Mexico: results from a large population-based nationwide survey. Diab Care 2003; 26: 2021-6.
5. Encuesta Nacional de Salud y Nutricion 2006. Institute Na-cional de Salud Publica; 2006.
6. Andrade F. Estimating diabetes and diabetes-free life expectancy in Mexico and seven major cities in Latin America and the Caribbean. Pan Am J Public Health 2009; 26(1): 9-16.
7. Hickman J, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.
8. Ryan MC, Wilson AM, Slavin J, et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetolo-gia 2004; 28(5): 1222-4.
9. Mendez-Sanchez N, Chavez-Tapia NC, Zamora-Valdes D, Medina-Santillan R, Uribe M. Hepatobilliary diseases and insulin resistance. Curr Med Chem 2007; 14(18): 1988-99.
10. Holstein A, Hize S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.
11. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43.
12. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol or cholestatic disease. J Hepatol 2000; 32:209-17.
13. Costa-Braganca AC, Alvarez da Silva MR. Prevalence of diabetes mellitus and impaired glucose tolerance in patients with decompensated cirrhosis being evaluated for liver transplantation: the utility of oral glucose tolerance test. Arq Gastroenterol 2010; 47(1): 22-7.
14. Arao M, Murase K, Kusakabe A, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 2003; 38: 355-60.
15. Mangia A, Schiavone G, Lezzi G, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol 1998; 93: 2363-7.
16. Mehta SH, Strathdee SA, Thomas DL. Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev 2001; 23(2): 302-12.
17. Lecube A, Hernandez C, Genesca J, et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection. Diabetes Care 2004; 27: 1171-5.
18. Fraser GM, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996; 32(7): 568-70.
19. Singal AK, Ayoola AE. Prevalence and factors affecting occurrence of type 2 diabetes mellitus in Saudi patients with chronic liver disease. Saudi J Gastroenterol 2008; 14(3): 118-21.
20. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
21. Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin. World J Gastroenterol 2008; 14(37): 5695-700.
22. Lagiou P, Kuper H, Stuver SO, et al. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92(13): 1096-9.
23. Davila JA. Editorial: Diabetes and hepatocellular carcinoma: What role does diabetes have in the presence of other known risk factors? Am J Gastroenterol 2010; 105: 632-4.
24. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28(1): 155-60.
25. Erikson SK. Nonalcoholic liver disease. J Lipid Res 2009; 50: S412-16.
26. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-18.
27. Gaiani S, Avogaro A, Bombonato GC, et al. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography. J Ultrasound 2009; 12(1): 1-5.
28. De Lusong MAA, Labio E, Daez L, Gloria V. Non-alcoholic fatty liver disease in the Philippines: comparable with other nations? World J Gastroenterol 2008; 14(6): 913-17.
29. Mendez-Sanchez N, Zamora-Valdes D, Vazquez-Fernandez F, Uribe M. Hepatocellular carcinoma in Hispanics. Ann Hepatol 2007; 6(4): 279-80.
30. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severe obese. Gastroenterology 2001; 121: 91-100.
31. Prashanth M, Ganesh HK, Vimal MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. JAPI 2009; 57: 205-10.
32. Amarapurkar DN, Patel ND, Kamani PM. Evaluating risk factors for development of non-alcoholic steatohepatitis in type-ll diabetes mellitus. Hepatitis Monthly 2008; 8(3): 197-200.
33. Nugent C, Younossi ZM. Evaluation and management of obesity-related NAFLD: epidemiology of NAFLD. Nat Clin Pract Gastroenterol Hepatol 2007; 4(8): 432-41.
34. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76.
35. Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterology 2005; 5: 27-35.
36. Jalihal A, Upali-Telisinghe P, Heng-Chong V. Profiles of autoimmune hepatitis in Brunei Darussalam. Hepatobiliary Pancreat Dis Int 2009; 8(6): 602-7.
37. Sampson MJ, Williams T, Heyburn PJ, et al. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 2000; 135(2): 170-3.
38. Conte D, Manachino D, Colli A, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998; 128(5): 370-3.
39. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: A changing scene. Am J Med 1991; 90: 445-9.
40. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schatner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic patients with chronic hepatitis C virus infections. Mayo Clinic Proc 2000; 75(4): 355-9.
41. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15(3): 280-8.
42. Data from the Direccion General de Epidemiologia; available at http://sinais.salud.gob.mx/mortalidad/
43. Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006; 101: 2752-9.
44. Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.
45. Negro F, Alaei M. Hepatitis C and type 2 diabetes. World J Gastroenterol 2009; 15(13): 1537-47.
46. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.